➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Dow
Boehringer Ingelheim
Moodys
Medtronic

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

NOCTIVA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Noctiva patents expire, and when can generic versions of Noctiva launch?

Noctiva is a drug marketed by Alyvant and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and five patent family members in thirty countries.

The generic ingredient in NOCTIVA is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

US ANDA Litigation and Generic Entry Outlook for Noctiva

A generic version of NOCTIVA was approved as desmopressin acetate by TEVA PHARMS USA on October 15th, 1997.

  Start Trial

US Patents and Regulatory Information for NOCTIVA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alyvant NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No   Start Trial   Start Trial   Start Trial
Alyvant NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 DISCN Yes No   Start Trial   Start Trial   Start Trial
Alyvant NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Alyvant NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for NOCTIVA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2712622 LUC00015 Luxembourg   Start Trial PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101
3225249 2019C/520 Belgium   Start Trial PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
2712622 122017000006 Germany   Start Trial PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504
2712622 C02712622/01 Switzerland   Start Trial PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Dow
Boehringer Ingelheim
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.